◎ Sugi Atlas

Atlas / Drug / Selegiline

Selegiline

drug
On this page

Also known as EmsamL-selegilineSelegilinadeprenyl(-)-R-deprenyl(R)-(-)-deprenylselegelineR-(-)-Deprenil(R)(-)deprenylR-(-)-deprenylR(-)-Deprenyl(-)-deprenylSID26752066R(-)deprenylL-deprenyl(R)-deprenyl(R)-DepryenylR-SelegilineZelaparL-Deprenyl

Summary

Selegiline (CHEMBL972) is an approved small-molecule geroprotector (ATC N04BD01) targeting MAOA and MAOB; indicated across 9 conditions including major depressive disorder and parkinson disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N04BD01
  • Targets: 2 (MAOA, MAOB)
  • Indications: 9 conditions
  • Clinical trials: 21
  • Chemistry: 187.28 Da · C13H17N

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL972
NameSelegiline
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID26757
ChEBICHEBI:9086
ATCN04BD01
Molecular formulaC13H17N
Molecular weight187.28
InChIKeyMEZLKOACVSPNER-GFCCVEGCSA-N

SMILES: C[C@H](CC1=CC=CC=C1)N(C)CC#C

IUPAC name: (2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine

Pharmacological roles (ChEBI): geroprotector.

Also known as: Emsam, L-selegiline, Selegilina, Selegiline, selegiline, deprenyl, (-)-R-deprenyl, (R)-(-)-deprenyl, selegeline, R-(-)-Deprenil, Selegeline, (R)(-)deprenyl

Parent form; salt/anhydrous children: CHEMBL1200904, CHEMBL5194110

Patent coverage: 7,219 distinct patent families (26,801 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
MAOAMonoamine oxidase AInhibition4.170.2%P21397
MAOBMonoamine oxidase BInhibition60%P27338

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Ferritin light chain, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Monoamine oxidase, Alpha-1A adrenergic receptor, Kappa-type opioid receptor, Amine oxidase [flavin-containing] B.

Bioactivity

ChEMBL activities: 178 potent at pChembl ≥ 5 of 254 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
MAOB10.77IC500.02nMCHEMBL_ACT_25576085
MAOB10.77IC500.02nMCHEMBL_ACT_5165981
MAOB8.89IC501.3nMCHEMBL_ACT_13413347
MAOB8.89IC501.3nMCHEMBL_ACT_13841528
P196438.56IC502.76nMCHEMBL_ACT_401421
MAOB8.48Ki3.3nMCHEMBL_ACT_15163796
MAOB8.41Ki3.9nMCHEMBL_ACT_15163803
MAOB8.41IC503.9nMCHEMBL_ACT_18541975
MAOB8.38IC504.15nMCHEMBL_ACT_29114750
MAOB8.26IC505.5nMCHEMBL_ACT_19048932
MAOB8.26IC505.5nMCHEMBL_ACT_19171924
MAOB8.21IC506.13nMCHEMBL_ACT_13298545
MAOB8.21IC506.13nMCHEMBL_ACT_13845849
P196438.21IC506.11nMCHEMBL_ACT_19171909
P196438.17IC506.74nMCHEMBL_ACT_13298546
P196438.17IC506.7nMCHEMBL_ACT_14712944
MAOB8.17IC506.8nMCHEMBL_ACT_18942342
MAOB8.16IC506.9nMCHEMBL_ACT_25480162
P196438.15IC507.08nMCHEMBL_ACT_10945255
P196438.15IC507nMCHEMBL_ACT_1244395
MAOB8.15IC507nMCHEMBL_ACT_18052499
MAOB8.15IC507nMCHEMBL_ACT_18667551
MAOB8.15IC507nMCHEMBL_ACT_2077467
P196438.15IC507nMCHEMBL_ACT_249333
MAOB8.15IC507nMCHEMBL_ACT_24995272
MAOB8.1IC508nMCHEMBL_ACT_18195014
P196438.1IC508nMCHEMBL_ACT_249328
MAOB8.05IC509nMCHEMBL_ACT_15706495
MAOB8.05Ki9nMCHEMBL_ACT_16761065
P196438.03IC509.4nMCHEMBL_ACT_249332

Target pathways

Aggregated over 2 target gene(s): MAOA, MAOB.

Top Reactome pathways

23 total, by targets touching each:

PathwayTargetsGenes
Amine Oxidase reactions2MAOA, MAOB
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB2MAOA, MAOB
Metabolism2MAOA, MAOB
Biological oxidations2MAOA, MAOB
Phase I - Functionalization of compounds2MAOA, MAOB
Neurotransmitter release cycle1MAOA
Neurotransmitter clearance1MAOA
Transmission across Chemical Synapses1MAOA
Neuronal System1MAOA
Cytokine Signaling in Immune system1MAOA
Disease1MAOA
Immune System1MAOA
Norepinephrine Neurotransmitter Release Cycle1MAOA
Enzymatic degradation of dopamine by COMT1MAOA
Enzymatic degradation of Dopamine by monoamine oxidase1MAOA
Dopamine clearance from the synaptic cleft1MAOA
Metabolism of serotonin1MAOA
Serotonin clearance from the synaptic cleft1MAOA
Signaling by Interleukins1MAOA
Defective MAOA causes BRUNS1MAOA
Metabolic disorders of biological oxidation enzymes1MAOA
Diseases of metabolism1MAOA
Interleukin-4 and Interleukin-13 signaling1MAOA

Dominant GO biological processes

GO termTargets
dopamine catabolic process2
biogenic amine metabolic process1
positive regulation of signal transduction1
serotonin catabolic process1
catecholamine metabolic process1
substantia nigra development1
hydrogen peroxide biosynthetic process1

Indications & clinical

Indications

9 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
major depressive disorder4MONDO:0002009MONDO:0002009
Parkinson disease4MONDO:0005180MONDO:0005180
cocaine dependence3MONDO:0005186EFO:0002610
borderline personality disorder3MONDO:0001156HP:0012076
depressive disorder3MONDO:0002050MONDO:0002050
nicotine dependence2MONDO:0008575EFO:0003768
prostate adenocarcinoma2MONDO:0005082EFO:0000673
methamphetamine dependence1MONDO:0005419EFO:0004701

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 21.

Phase distribution

PhaseTrials
PHASE28
PHASE44
PHASE33
Not specified3
PHASE12
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00531947PHASE4COMPLETEDPhase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
NCT00535262PHASE4TERMINATEDA Pilot Study Assessing EmSam in Bipolar Depression
NCT02225548PHASE4UNKNOWNSagene 2014 - Parkinson’s Disease and Erectile Dysfunction
NCT04870372PHASE4COMPLETEDSelegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease
NCT00032929PHASE3COMPLETEDSelegiline Transdermal System for the Treatment of Cocaine Dependence - 1
NCT00285766PHASE3COMPLETEDSafety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
NCT01912391PHASE3COMPLETEDClinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder
NCT00000188PHASE2COMPLETEDSelegiline in Treatment of Cocaine Dependence - 2
NCT00000201PHASE2COMPLETEDPharmacological Modulation of Cocaine Effects - 1
NCT00000336PHASE2COMPLETEDSelegiline in Outpatient Treatment for Cocaine Dependence - 1
NCT00129311PHASE2COMPLETEDUsefulness of Selegiline as an Aid to Quit Smoking - 1
NCT00439413PHASE2COMPLETEDSelegiline for Smoking Cessation - 1
NCT01330030PHASE2COMPLETEDSelegiline Patch for Treatment of Nicotine Dependence
NCT01495195PHASE2COMPLETEDCombined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior
NCT04586543PHASE2UNKNOWNClinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
NCT00000337PHASE1COMPLETEDInfusion Laboratory: Protocol 1 - Selegeline - 2
NCT00033072PHASE1UNKNOWNAssessment of Potential Interactions Between Methamphetamine and Selegiline - 1
NCT00456976EARLY_PHASE1COMPLETEDEfficacy of Selegiline in Negative Symptoms of Schizophrenia
NCT00390923Not specifiedTERMINATEDTesting a Full Substitution Therapy Approach As Treatment of Tobacco Dependence
NCT04130087Not specifiedUNKNOWNSelegiline and Reward Processing
NCT06607744Not specifiedCOMPLETEDDetermine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

174 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
TEDIZOLIDChEMBL + PubChemPhase 4 (approved)MAOA, MAOB
CLOTRIMAZOLEChEMBLPhase 4 (approved)MAOA, MAOB
DANTHRONChEMBLPhase 4 (approved)MAOA, MAOB
FENTANYLChEMBLPhase 4 (approved)MAOA, MAOB
IPRONIAZIDChEMBLPhase 4 (approved)MAOA, MAOB
LINEZOLIDChEMBLPhase 4 (approved)MAOA, MAOB
MENADIONEChEMBLPhase 4 (approved)MAOA, MAOB
METHYLENE BLUE CATIONChEMBLPhase 4 (approved)MAOA, MAOB
MICONAZOLEChEMBLPhase 4 (approved)MAOA, MAOB
MOCLOBEMIDEChEMBLPhase 4 (approved)MAOA, MAOB
PARGYLINEChEMBLPhase 4 (approved)MAOA, MAOB
PHENELZINEChEMBLPhase 4 (approved)MAOA, MAOB
PIOGLITAZONEChEMBLPhase 4 (approved)MAOA, MAOB
PRIMAQUINEChEMBLPhase 4 (approved)MAOA, MAOB
RASAGILINEChEMBLPhase 4 (approved)MAOA, MAOB
ROSIGLITAZONEChEMBLPhase 4 (approved)MAOA, MAOB
SAFINAMIDEChEMBLPhase 4 (approved)MAOA, MAOB
TOLOXATONEChEMBLPhase 4 (approved)MAOA, MAOB
TRANYLCYPROMINEChEMBLPhase 4 (approved)MAOA, MAOB
TROGLITAZONEChEMBLPhase 4 (approved)MAOA, MAOB
CURCUMINChEMBLPhase 3MAOA, MAOB
IDAZOXANChEMBLPhase 3MAOA, MAOB
QUERCETINChEMBLPhase 3MAOA, MAOB
RESVERATROLChEMBLPhase 3MAOA, MAOB
BROFAROMINEChEMBLPhase 2MAOA, MAOB
CIGLITAZONEChEMBLPhase 2MAOA, MAOB
CLORGILINEChEMBLPhase 2MAOA, MAOB
DAIDZEINChEMBLPhase 2MAOA, MAOB
FORMONONETINChEMBLPhase 2MAOA, MAOB
GENISTEINChEMBLPhase 2MAOA, MAOB
LADOSTIGILChEMBLPhase 2MAOA, MAOB
LUTEOLINChEMBLPhase 2MAOA, MAOB
MOFEGILINEChEMBLPhase 2MAOA, MAOB
PHENAMAZOLINEChEMBLPhase 2MAOA, MAOB
PIPERINEChEMBLPhase 2MAOA, MAOB
SEMBRAGILINEChEMBLPhase 2MAOA, MAOB
SUTEZOLIDChEMBLPhase 2MAOA, MAOB
TIOXOLONEChEMBLPhase 2MAOA, MAOB
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)MAOA
REGORAFENIBChEMBL + PubChemPhase 4 (approved)MAOA
TAFAMIDISChEMBL + PubChemPhase 4 (approved)MAOA
ABROCITINIBChEMBLPhase 4 (approved)MAOA
AMILORIDEChEMBLPhase 4 (approved)MAOA
ANISINDIONEChEMBLPhase 4 (approved)MAOA
ARIPIPRAZOLEChEMBLPhase 4 (approved)MAOA
ATALURENChEMBLPhase 4 (approved)MAOA
BENOXAPROFENChEMBLPhase 4 (approved)MAOA
BIFONAZOLEChEMBLPhase 4 (approved)MAOA
CABOZANTINIBChEMBLPhase 4 (approved)MAOA
CHLOROPROCAINEChEMBLPhase 4 (approved)MAOA
COCAINEChEMBLPhase 4 (approved)MAOA
DEBRISOQUINChEMBLPhase 4 (approved)MAOA
DELAVIRDINEChEMBLPhase 4 (approved)MAOA
DEQUALINIUMChEMBLPhase 4 (approved)MAOA
DEXTROAMPHETAMINEChEMBLPhase 4 (approved)MAOA
DISULFIRAMChEMBLPhase 4 (approved)MAOA
DONEPEZILChEMBLPhase 4 (approved)MAOB
ETHOPROPAZINEChEMBLPhase 4 (approved)MAOA
ETHYNODIOL DIACETATEChEMBLPhase 4 (approved)MAOA
FAMOTIDINEChEMBLPhase 4 (approved)MAOA

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot